Abstract: Background: Atopic dermatitis (AD) affecting the head and neck (H&N) area poses a clinical challenge due to the unique anatomical and physiological features of this region. Despite its well-documented impact on quality of life (QoL), evidence on the effectiveness of tralokinumab in treating AD specifically in the H&N area remains limited. Objective: To assess the clinical outcomes of tralokinumab in AD patients with H&N involvement, informing clinical decision-making and improving patient care. Methods: A multicenter, retrospective cohort study across 5 Italian tertiary referral hospitals. Patients were stratified by H&N involvement, and treatment outcomes were assessed using the Eczema Area and Severity Index (EASI), EASI H&N, Investigator Global Assessment (IGA), Numerical Rating Scale (NRS) pruritus, NRS sleep, Dermatology Life Quality Index, Patient-Oriented Eczema Measure, and Atopic Dermatitis Control Tool. Results: Among 211 patients, 145 (68.7%) had H&N involvement. A significant reduction in EASI H&N scores from baseline to weeks 12–16 (38.1%) and week 24 (54.5%) was achieved. Significant improvements in IGA, NRS
Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study
Martina Maurelli;Giampiero Girolomoni;
2026-01-01
Abstract
Abstract: Background: Atopic dermatitis (AD) affecting the head and neck (H&N) area poses a clinical challenge due to the unique anatomical and physiological features of this region. Despite its well-documented impact on quality of life (QoL), evidence on the effectiveness of tralokinumab in treating AD specifically in the H&N area remains limited. Objective: To assess the clinical outcomes of tralokinumab in AD patients with H&N involvement, informing clinical decision-making and improving patient care. Methods: A multicenter, retrospective cohort study across 5 Italian tertiary referral hospitals. Patients were stratified by H&N involvement, and treatment outcomes were assessed using the Eczema Area and Severity Index (EASI), EASI H&N, Investigator Global Assessment (IGA), Numerical Rating Scale (NRS) pruritus, NRS sleep, Dermatology Life Quality Index, Patient-Oriented Eczema Measure, and Atopic Dermatitis Control Tool. Results: Among 211 patients, 145 (68.7%) had H&N involvement. A significant reduction in EASI H&N scores from baseline to weeks 12–16 (38.1%) and week 24 (54.5%) was achieved. Significant improvements in IGA, NRS| File | Dimensione | Formato | |
|---|---|---|---|
|
Avallone tralo H&N Dermatitis 2026.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
896.86 kB
Formato
Adobe PDF
|
896.86 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



